Pharmacyclics Announces Presentation Of Pooled Analysis Of Xcytrin(R) For Lung Cancer Brain Metastases

... Pharmacyclics, Inc. (Nasdaq: PCYC) today announced the presentation of pooled results from two randomized Phase 3 clinical trials, which indicate that Xcytrin(R) (motexafin gadolinium) Injection combined with whole brain radiation therapy (WBRT) significantly prolonged time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases. [click link for full article] ...